Ranbaxy Laboratories Ltd (RANB.BO)
354.15INR
3:47pm IST
Rs1.75 (+0.50%)
Rs352.40
Rs352.90
Rs359.35
Rs349.00
352,028
165,419
Rs578.30
Rs342.75
RANB.BO
About
Overall
| Beta: | 1.35 |
| Market Cap (Mil.): | Rs149,270.00 |
| Shares Outstanding (Mil.): | 423.10 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| RANB.BO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.37 | 30.65 |
| EPS (TTM): | -4.70 | -- | -- |
| ROI: | -- | 19.50 | 18.83 |
| ROE: | -- | 20.27 | 19.74 |
EU fines Ranbaxy, others for blocking cheaper drugs
BRUSSELS - European antitrust regulators fined nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, a total of 146 million euros for blocking the supply of a cheaper anti-depressant to the market, the first EU sanction against such deals.
Ranbaxy eyes U.S. drug launches with sales exclusivity
MUMBAI, June 13 - Ranbaxy Laboratories, India's No.1 drugmaker by sales, plans to file three to four generic drug applications every year that can earn it a six-month marketing exclusivity in the United States, the company's chief executive said on Thursday.
Pharma stocks gain on value-buying
Reuters Market Eye - Shares in pharmaceutical companies are leading the gains on Tuesday due to factors such as value-buying and expectations that promoters may increase stake in some companies, dealers say.
EU to fine Ranbaxy, others for blocking generic drugs
BRUSSELS - A European regulator will fine Denmark's Lundbeck , India's Ranbaxy and seven other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against "pay-for-delay" deals.
Ranbaxy slumps after Daiichi Sankyo says was misled
MUMBAI - Shares in Ranbaxy Laboratories Ltd fell as much as 10.7 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believed former shareholders of the Indian company hid information regarding U.S. regulatory probes.
UPDATE 1-Ranbaxy slumps after Daiichi Sankyo says was misled
(Adds response from Singh family, details; updates share price)
Ranbaxy shares slump after Daiichi Sankyo says misled
MUMBAI - Ranbaxy Laboratories Ltd slumped as much as 9.37 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding U.S. regulatory probes.
MARKET EYE-Indian shares fall; Ranbaxy, L&T slump
* India's main BSE index falls 0.66 percent and the broader NSE index is down 0.8 percent, heading towards their fourth consecutive session of declines. * Asian stocks slid and the dollar rose to a 4-1/2 year high after Fed Chairman Ben Bernanke's remarks sparked worries of a reduction in U.S. monetary stimulus and after data showed China's factory activity shrank for the first time in seven months in May. * Ranbaxy Laboratories Ltd slumps 6 percent after majority shareholder Daiichi Sankyo
Ranbaxy shares slump after Daiichi Sankyo says misled over probes
MUMBAI, May 23 - Ranbaxy Laboratories Ltd slumped as much as 6.6 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding U.S. regulatory probes.
Daiichi Sankyo says it was misled over Ranbaxy probes
MUMBAI - Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
